Ye Xuying: Accumulate Experience and Innovate
Release time:
2023-03-21
In Jianfeng Health Technology Company, when it comes to people who know the production equipment best, most people think of Ye Xuying first.
Ye Xuying entered Peak Health in 2015 and has been the manager of the production department. He is mainly responsible for the production management of three workshops: health care products, Chinese herbal pieces and plant extraction. He said that he has been engaged in drug and extract related work since graduation, and has been in the production line for more than 20 years. No matter what type of production line, most of the equipment principles are similar, and he is very interested in mechanical equipment. As long as you look at the circuit diagram and know the principle of the equipment, you will basically understand the operating performance of the equipment. Therefore, in the production process, if there is a problem with the equipment, the operator will first find him to solve it. However, he has always advocated that workshop employees can carry out simple tasks such as equipment maintenance by themselves, because they can improve efficiency. Especially in the clean area, it takes a long time for the mechanic to clean and disinfect. If the employee can solve the small problem by himself, the downtime of the equipment can be greatly saved. When
Ye Xu Ying first entered the company, he found that the employees in the workshop were not familiar with the performance of the equipment. There were still some differences between the laboratory process and the production on the production line. Moreover, each employee's understanding and acceptance ability was different. Someone needed to convert the experimental process into the workshop production process and formulate the operation procedures to ensure the smooth production, reduce errors and ensure the product quality. So Ye Xuying, who had just entered the company, became the "bridge" and first improved the product technology in the workshop. In recent years, he has also trained five master operators who can master job operation skills.
The understanding of the equipment process also laid a solid foundation for Ye Xuying's technological innovation and technological transformation. peak health of the main products of rhodiola rosea broken ganoderma lucidum spore powder soft capsule (jingzhi cikang) main raw materials by rhodiola rosea, ganoderma lucidum spore powder, ginseng and other 6 kinds of chinese herbal medicine composition. In the process of pressing the soft capsule, the contents are bonded together after repeated friction and heat generation in the injection pump, resulting in the particle size of the material becoming larger to the level that does not meet the conditions to be met for pressing the soft capsule. When the rubber is pressed, it is easy to leak oil from gaps, thus the soft capsule cannot be pressed continuously, and even the whole batch of soft capsules is scrapped. This problem once restricted the production of Jingzhi Cikang. However, the contents of most soft capsules on the market are relatively single. As long as the fineness of the contents is ensured, the qualified rate of soft capsules will be very high. Because there is no ready-made reference experience, Ye Xuying began his exploration. He optimized the pressing parameters and content preparation process according to the properties of solid materials. He used the existing wall-breaking equipment in the workshop and adopted the wall-breaking crushing treatment method to successfully eliminate the risk of oil leakage of soft capsules, greatly improving the yield of finished products, and theoretically making the products easier to be absorbed by human body.
When it comes to these innovations and renovations, Ye Xuying is like a treasure. Before, a company that made dried blueberries found Spike Health to help decolorize the sugar water soaked in blueberries. During the chat, they said that they wanted to press tablets with blueberry extract to make tableted candy. However, due to the strict requirements on the content of proanthocyanidins, they could not add too many auxiliary materials, and several companies could not solve the technical problem of tableting. In the process of tablet compression, auxiliary materials need to be added for bonding. General adhesives are solid. The content of proanthocyanidins will be reduced if more is added, but the compression is not good if less is added. After learning about this situation, Ye Xuying's brain turned again, since the solid is not good, what about the liquid? The nature of blueberry extract is quite special, and it can dissolve with many kinds of organic solvents, so he started a round of attempts by using this characteristic. At present, it has successfully provided 3 pilot samples to the other party, and has reached the quality requirements of tablets in terms of appearance color, product content, hardness, etc. The preparation method also applied for an invention patent.
Ye Xuying said that his innovations and inventions are all derived from years of work experience and familiarity with equipment and technology. In recent years, he has applied for 6 patents, participated in a number of government projects, developed a number of new products, and was also rated as the 2022 "Outstanding Enterprise Science and Technology Talent" in Wucheng District ". In his heart, there is a good wish, that is, Peak Health can achieve breakthroughs with the joint efforts of everyone, use modern technology to accelerate the progress of digitization, build a digital chemical factory, and strengthen and grow the health industry. And he is working with his colleagues to contribute to this goal. (Ni Yingzhen Chen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31